- Home
- PNFPP vs SCLXW Comparison
PNFPP vs SCLXW Comparison
Compare PNFPP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNFPP
- SCLXW
- Stock Information
- Founded
- PNFPP N/A
- SCLXW N/A
- Country
- PNFPP United States
- SCLXW United States
- Employees
- PNFPP 3517
- SCLXW 117
- Industry
- PNFPP Major Banks
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- PNFPP Finance
- SCLXW Health Care
- Exchange
- PNFPP Nasdaq
- SCLXW Nasdaq
- Market Cap
- PNFPP N/A
- SCLXW N/A
- IPO Year
- PNFPP N/A
- SCLXW N/A
- Fundamental
- Price
- PNFPP $24.95
- SCLXW $0.11
- Analyst Decision
- PNFPP
- SCLXW
- Analyst Count
- PNFPP 0
- SCLXW 0
- Target Price
- PNFPP N/A
- SCLXW N/A
- AVG Volume (30 Days)
- PNFPP N/A
- SCLXW 4.0K
- Earning Date
- PNFPP N/A
- SCLXW 03-07-2025
- Dividend Yield
- PNFPP N/A
- SCLXW N/A
- EPS Growth
- PNFPP N/A
- SCLXW N/A
- EPS
- PNFPP N/A
- SCLXW N/A
- Revenue
- PNFPP N/A
- SCLXW $55,152,000.00
- Revenue This Year
- PNFPP N/A
- SCLXW N/A
- Revenue Next Year
- PNFPP N/A
- SCLXW N/A
- P/E Ratio
- PNFPP N/A
- SCLXW N/A
- Revenue Growth
- PNFPP N/A
- SCLXW 22.02
- 52 Week Low
- PNFPP N/A
- SCLXW $0.18
- 52 Week High
- PNFPP N/A
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- PNFPP 51.98
- SCLXW N/A
- Support Level
- PNFPP $24.66
- SCLXW N/A
- Resistance Level
- PNFPP $25.00
- SCLXW N/A
- Average True Range (ATR)
- PNFPP 0.23
- SCLXW 0.00
- MACD
- PNFPP -0.00
- SCLXW 0.00
- Stochastic Oscillator
- PNFPP 45.79
- SCLXW 0.00
About PNFPP Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. Pinnacle operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.